FBIO — Fortress Biotech Balance Sheet
0.000.00%
- $91.02m
- -$85.27m
- $63.26m
Annual balance sheet for Fortress Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 306 | 178 | 80.9 | 57.3 | 79.4 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 23.8 | 28.3 | 15.4 | 10.4 | 29.9 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 346 | 230 | 117 | 90.4 | 124 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 34.1 | 33 | 23.5 | 17.1 | 14.8 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 397 | 294 | 168 | 144 | 186 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 101 | 128 | 84.9 | 71.4 | 49.7 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 288 | 253 | 145 | 121 | 136 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 109 | 41.7 | 22.5 | 22.7 | 49.9 |
| Total Liabilities & Shareholders' Equity | 397 | 294 | 168 | 144 | 186 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |